Navigation Links
Claritin(R) Renews Sponsorship With Allergy Sufferer and NASCAR Star Carl Edwards
Date:2/12/2009

- Partnership Drives Home Importance of Being Alert and Focused on and off the Racetrack -

KENILWORTH, N.J., Feb. 12 /PRNewswire-FirstCall/ -- Schering-Plough (NYSE: SGP), maker of the top-selling allergy medicine, CLARITIN, announces its second Sprint Cup racing season as a sponsor of NASCAR star and long-time allergy sufferer Carl Edwards. Edwards, who takes non-drowsy CLARITIN to treat his allergy symptoms, will drive the No. 99 CLARITIN Ford Fusion during the April NASCAR Sprint Cup race at Talladega Superspeedway, NASCAR's most competitive track.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090212/NY69974 )

"As a driver who races at speeds up to 180 miles an hour, I can't risk taking an allergy medicine that might make me drowsy," said Edwards. "I've continued my partnership with CLARITIN because it works hard to relieve my worst allergy symptoms without drowsiness, so I can think and react fast."

Last year, Edwards was runner-up in both the 2008 NASCAR Sprint Cup Series and NASCAR Nationwide Series point standings. He also was the voice of the CLARITIN Clear To Drive(SM) campaign which emphasizes the importance of reading medicine labels to check for warnings about drowsiness before getting behind the wheel of a car.

"We are thrilled to continue our relationship with Carl Edwards, and we're proud of his accomplishments," said TJ Higgins, Group Vice President, Marketing, Schering-Plough Consumer HealthCare. "Carl has been instrumental in letting consumers know that CLARITIN effectively relieves both indoor and outdoor allergy symptoms without drowsiness and is safe to take when driving."

For more information on allergies and treatments, visit www.CLARITIN.com.

About CLARITIN(R)

All CLARITIN(R) brand products are available without a prescription, including: CLARITIN(R) Tablets, a once-daily, full prescription strength, non-drowsy formulation; CLARITIN(R) RediTabs(R) Tablets, a novel once-daily formulation in a quickly dissolving tablet for ages 6 and older; CLARITIN(R) Liqui-Gels(R), a once-daily formulation in an easy-to-swallow liquid-filled capsule; CLARITIN-D(R) 24-hour and 12-hour Extended Release Tablets, with the decongestant pseudoephedrine, now located behind the counter; CHILDREN'S CLARITIN(R) Syrup, a liquid formulation for children ages 2 and older in grape and fruit flavors; and CHILDREN'S CLARITIN(R) Grape Chewables, a chewable tablet for children ages 2 and older.

CLARITIN(R) is the No. 1 physician-recommended and pediatrician-recommended non-drowsy over-the-counter allergy brand. The CLARITIN(R) Rx-to-OTC switch in 2002 was the largest switch ever--and the first and only for a non-drowsy antihistamine. For more information on allergies and treatment, visit www.CLARITIN.com.

About Schering-Plough

Schering-Plough Consumer Health Care is the U.S. over-the-counter (OTC) and consumer products business unit of Schering-Plough an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to potential market for CLARITIN. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A. "Risk Factors" in the third quarter 2008 10-Q, filed October 29, 2008.


'/>"/>
SOURCE Schering-Plough
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available
2. FDA Approves Labeling Change for Non-Drowsy CLARITIN(R)
3. TodayMD Renews Race Sponsorship With Alegra Motorsports For A Third Year
4. The American College of Cardiology Renews its Publishing Partnership With Elsevier
5. China Medicine Renews Contract with CCG Investor Relations
6. SEIUs Andy Stern Renews Call to Fix Nations Broken Health Care System, Ease Financial Strain on Working Families, Economy
7. Arthritis Foundation Renews Comprehensive Marketing Contract with Merkle
8. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
9. AMERIGROUP Renews Contract with Tennessee
10. WHO Report Says 9.7 Million at Risk of Death from AIDS Today; AHF Renews Call for US Congress to Commit to Scale up Treatment to Seven Million Lives
11. Blue Cross Blue Shield of Arizona Renews EDS Information Technology Services Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
Breaking Medicine Technology: